35 citations
,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
70 citations
,
December 2008 in “Cancer Research” CXCR2 in skin cells promotes tumor growth.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
40 citations
,
March 2019 in “Nature Communications” CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
11 citations
,
January 2009 in “World Journal of Gastroenterology” A woman with both Cronkhite-Canada syndrome and myelodysplastic syndrome improved significantly with corticosteroid treatment.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
December 2025 in “Scientific Reports” Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
2 citations
,
June 2025 in “International Journal of Molecular Sciences” Carthamus caeruleus root juice may reduce inflammation.
9 citations
,
January 2024 in “International Journal of Dermatology”
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.
October 1990 in “Pediatric Research” Nocturnal calcium infusions improved a boy's severe rickets without causing hair loss.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
April 2012 in “Informa Healthcare eBooks” Some drugs for inflammation may cause psoriasis-like hair loss.
9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.
2 citations
,
January 2022 in “Genetics Research” Using hemocoagulase with platelet-rich plasma in hip replacement can lessen blood loss and improve healing and blood clotting.
3 citations
,
September 2020 Dyclonine can effectively reduce skin issues by inhibiting the TRPV3 channel.
March 2019 in “Journal der Deutschen Dermatologischen Gesellschaft” Rothmund-Thomson syndrome type 2 can cause chronic, poorly healing wounds.
16 citations
,
August 2002 in “Journal of Interferon and Cytokine Research” A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.